Cancer ImmunotherapyCancer Drug Resistance
Hemorrhage-activated NRF2 in tumor-associated macrophages drives cancer growth, invasion, and immunotherapy resistance
Journal of Clinical Investigation 2024-02-01
Dominik J. Schaer, Nadja Schulthess-Lutz, Florence Vallelian
Abstract
Microscopic hemorrhage is a common aspect of cancers. Using spatial transcriptomics, we found that NRF2-activated myeloid cells possessing characteristics of procancerous TAMs cluster in perinecrotic hemorrhagic tumor regions. We identified heme as a pivotal microenvironmental factor steering macrophages toward protumorigenic activities.
Key Findings
- Intratumoral hemorrhage drives cancer-promoting TAMs via NRF2 activation
- Heme from red blood cell breakdown activates NRF2 in macrophages
- NRF2-activated TAMs are resistant to reprogramming by IFN-γ and anti-CD40
- Spatial transcriptomics revealed NRF2-TAMs cluster in hemorrhagic regions
Clinical Significance
First study identifying hemorrhage-driven NRF2 activation as a driver of immunotherapy resistance through TAM reprogramming.
Citation
Schaer, D.J. et al. (2024). Hemorrhage-activated NRF2 in TAMs. Journal of Clinical Investigation.
DOI: 10.1172/JCI174528